Melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Reasons for the continuity include resilience from the Bronze Age collapse, which was mostly true for inland cities such as Tel Megiddo and Tel Abel Beth Maacah. Elsewhere, European-related and East African-related components were added to the population, from a north-south and south-north gradient respectively. Late Neolithic and Bronze Age Europeans and Somalis were used as representatives. A 2025 study (by Lipson et al.) suggested that the patrilineal origins of ancient Israelites were likely to be genetically heterogeneous. In addition, various Y haplogroups of ancient Near Eastern origin associated with the Cohanim were due to non-patrilineal descendants of Cohanim adopting the Cohanim identity. They might've arose due to sporadic coupling with non-Cohenite Judeans, marriage with converted foreigners such as Babylonians or Greco-Romans, or perhaps from non-paternity events. However, at least two Cohen branches (CB-01 and CB-02) appear to trace back to 'early 1st millennium BCE priestly ancestors'.
While transformed, he wields the D-Sword Vega (ディーソード・ベガ, Dī Sōdo Bega), which possesses a gun function and allows him to perform the Vega Tornado Slash (ベガトルネードスラッシュ, Bega Torunēdo Surasshu) attack and the Vega Slash (ベガスラッシュ, Bega Surasshu) finisher. He also rides the S.P.D. Helicopter (S.P.D.ヘリコプター, Esu Pī Dī Herikoputā). Doggie Kruger is voiced by Tetsu Inada (稲田 徹, Inada Tetsu).
Insect infestations, food shortages, and the destruction of provisions by rain and humidity presented ongoing challenges. Despite these hardships, Humboldt remained healthy and productive, documenting his scientific observations. Progressing up the Orinoco, the expedition reached Pararuma, where they met missionaries and Father Bernardo Zea, missionary of Atures and Maipures, who agreed to guide them further. Due to the rapids, a smaller canoe was acquired. The new canoe, hollowed from a single tree, was forty feet long and less than three feet wide. The arrangement left little space, resulting in cramped conditions for the passengers, supplies, and animal specimens. Native canoemen occupied the bow, and a mulatto servant from Cumana managed provisions and cooking. Insects continued to be a significant nuisance, and local methods of mitigation included sleeping in smoke-filled ovens, burying oneself in sand, or using mud and turtle oil as repellents. Humboldt also observed the use of rubber stoppers provided by local Natives. As the river narrowed, navigation through the Great Cataracts of Atures and Maipures required both paddling and hauling the canoe overland. Humboldt and Bonpland stayed at Father Zea’s mission during this process, where they observed a declining Native population, poor living conditions, and ongoing disease. Insect bites became a dominant hardship. Beyond the cataracts, the expedition entered little-documented territory.
=== Obesity === It has been observed that increased number of pro-inflammatory macrophages within obese adipose tissue contributes to obesity complications including insulin resistance and diabetes type 2. The modulation of the inflammatory state of adipose tissue macrophages has therefore been considered a possible therapeutic target to treat obesity-related diseases. Although adipose tissue macrophages are subject to anti-inflammatory homeostatic control by sympathetic innervation, experiments using ADRB2 gene knockout mice indicate that this effect is indirectly exerted through the modulation of adipocyte function, and not through direct Beta-2 adrenergic receptor activation, suggesting that adrenergic stimulation of macrophages may be insufficient to impact adipose tissue inflammation or function in obesity.
Sources: en.wikipedia.org
Pardee (1912), neurologist, husband of Abby Rockefeller Alfred Sturtevant (1912), geneticist, protege of Thomas Hunt Morgan and winner of the National Medal of Science James Chapin (1916), ornithologist; 17th president of The Explorers Club Seeley G. Mudd (1917), physician and philanthropist, former dean of Keck School of Medicine of USC Harold Alexander Abramson (1919), early advocate of Psychedelic therapy Augustus Braun Kinzel (1919), metallurgist and first president of the National Academy of Engineering William V. Silverberg (1919), founder of the American Academy of Psychoanalysis and Dynamic Psychiatry Sherman Fairchild* (1920), founder of Fairchild Aircraft, Fairchild Industries, Fairchild Camera and Instrument as well as Fairchild Semiconductor Francis Bitter (1925), physicist, inventor of Bitter electromagnets Howard Bruenn (1925), personal physician to Franklin D. Roosevelt Albert Charles Smith (1926), botanist, former director of the National Museum of Natural History and the Arnold Arboretum Konrad Lorenz* (1926), winner of the Nobel Prize in Physiology or Medicine Jerrold R. Zacharias (1926), nuclear physicist, professor at Massachusetts Institute of Technology Andrew Streitwieser (1927), chemist known for his contributions to physical organic chemistry Julian M. Sturtevant (1927), chemist at Yale University Raymond D.
The history of wound care spans from prehistory to modern medicine. Wounds naturally heal by themselves, but hunter-gatherers would have noticed several factors and certain herbal remedies would speed up or assist the process, especially if it was grievous. In ancient history, this was followed by the realisation of the necessity of hygiene and the halting of bleeding, where wound dressing techniques and surgery developed. Eventually the germ theory of disease also assisted in improving wound care.
The People's Republic of China, which had started to move towards capitalism in the late 1970s and faced public anger after the 1989 Tiananmen Square protests and massacre in Beijing, moved even more quickly towards free-market economics in the 1990s, framing this mixed economy as "socialism with Chinese characteristics". McDonald's and Pizza Hut both entered the country in the second half of 1990, the first American chains in China (aside from Kentucky Fried Chicken, which had entered in 1987). Stock markets were established in Shenzhen and Shanghai in late 1990 as well. Restrictions on car ownership were loosened in the early 1990s and caused the bicycle to decline as a form of transport by 2000. The move to capitalism has increased the economic prosperity of China, but many people still live in poor conditions and work for companies for very low wages and in dangerous and poor conditions. Many other Third World countries had seen involvement from the United States and/or the Soviet Union, but solved their political conflicts because of the removal of the ideological interests of those superpowers. As a result of the apparent victory of democracy and capitalism in the Cold War, many more countries adapted these systems, which also allowed them access to the benefits of global trade, as economic power became more prominent than military power in the international arena.
==== II. Immunotherapy ==== In addition to permeating the blood brain barrier, ultrasound and microbubble therapy can alter the tumor environment and serve as an immunotherapeutic treatment. High-intensity focused ultrasound (HIFU) alone triggers an immune response, speculated to be through facilitating the release of tumor antigens for immune cell recognition, activating antigen-presenting cells and promoting their infiltration, combatting tumor immunosuppression, and promoting a Th1 cell response. Typically, HIFU is used for thermal ablation of tumors. Low-intensity focused ultrasound (LIFU) in combination with microbubbles has also shown to stimulate immunostimulatory effects, inhibiting tumor growth and increasing endogenous leukocyte infiltration. Furthermore, lowering the acoustic power required for HIFU yields a safer treatment for the patient, as well as diminished treatment time. Though the treatment itself shows potential, a combinatorial treatment is speculated to be required for a complete treatment. Ultrasound and microbubble treatment without additional drugs impeded the growth of small tumors but required a combinatorial drug treatment to affect medium-sized tumor growth. With their immune stimulating mechanism, ultrasound and microbubbles offer a unique ability to prime or enhance immunotherapies for more effective cancer treatment.
Most people with back pain do not experience chronic severe pain but rather persistent or intermittent pain that is mild or moderate. Still, chronic back pain symptoms, defined as repeated or persistent pain for at least 3 months within the past 12 months, affected 34.4% of a nationwide sample of adults in mild form, 25.1% in moderate form, and 13% in (very) severe form. In most cases of herniated disks and stenosis, rest, injections or surgery have similar general pain-resolution outcomes on average after one year. In the United States, acute low back pain is the fifth most common reason for physician visits and causes 40% of missed work days. It is the single leading cause of disability worldwide. According to the World Health Organization, approximately 90% of all low back pain cases are non-specific, meaning that no clear structural cause can be identified.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.